REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AL102, a Gamma Secretase Inhibitor

AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population   AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in T2W signal intensity REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Oct.

REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger with Biosight, Ltd. (“Biosight”), pursuant to which Ayala acquired Biosight.

Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT, Israel and

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Society for

Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology asset to Ayala’s portfolio with data anticipated in the first half of 2024 REHOVOT and TEL AVIV, Israel and MONMOUTH JUNCTION, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc.

Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment in Phase 3 continuing as planned REHOVOT, Israel & MONMOUTH JUNCTION, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc.

Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company to host conference call and webcast to discuss updated Phase 2 results on Wednesday, June 7 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., June 05, 2023

ASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2 mg once daily (the selected Phase 3 dose) Tumor response, volume and T2 signal reduction were observed earlier in the 1.2 mg once daily group, with deeper and

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced first-quarter 2023 financial results and provided a corporate update. “Our immediate priority is to complete enrollment in our